Baidu
map

Lancet Oncol:阿瑞吡坦对生物制剂所致严重瘙痒治疗有效

2012-09-29 网络 网络

  瘙痒是抗EGFR抗体治疗和酪氨酸激酶抑制剂治疗的常见副反应。Daniele Santini等设计了一个单中心队列研究以评估神经肽受体抑制剂阿瑞吡坦对生物制剂所引起的严重瘙痒的治疗效果。本研究发表在Lancet Oncol 9月最新的在线期刊上。   本研究是单中心、前瞻性队列研究,研究者连续纳入45名使用生物制剂进行治疗的转移性实体肿瘤的门诊患者。所纳入的受试者都在位于意大利罗马的Campu

  瘙痒是抗EGFR抗体治疗和酪氨酸激酶抑制剂治疗的常见副反应。Daniele Santini等设计了一个单中心队列研究以评估神经肽受体抑制剂阿瑞吡坦对生物制剂所引起的严重瘙痒的治疗效果。本研究发表在Lancet Oncol 9月最新的在线期刊上。

  本研究是单中心、前瞻性队列研究,研究者连续纳入45名使用生物制剂进行治疗的转移性实体肿瘤的门诊患者。所纳入的受试者都在位于意大利罗马的Campus Bio-Medico Hospital of Rome接受治疗,研究时间为2010年9月至2011年11月。研究者将受试者分为2组:难治组或初发组,难治组的患者瘙痒反复发作接受标准治疗,初发组的患者既往未接受过瘙痒的治疗。在至少一周的系统性标准治疗后,难治组的患者接受阿瑞吡坦治疗,剂量为第一天125mg,第三和第五天各80mg。在初发组,患者接受的治疗方案与难治组一致,接受治疗的时间为第一次出现严重瘙痒反应时。瘙痒的程度通过视觉模拟评分法(VAS)进行评估。研究的原发终点为平均VAS评分出现变化。本研究在ClinicalTrials.gov注册。

  在难治组中,VAS的基线得分为8.00,阿瑞吡坦治疗一周后的评分为1.00,提示阿瑞吡坦能显着缓解瘙痒症状。在初发组中,也能得出相似的结论,VAS的基线得分为8.00,阿瑞吡坦治疗一周后的评分为0.00。91%的患者对阿瑞吡坦治疗有反应(瘙痒程度减轻50%以上),仅有13%的患者出现瘙痒的复发。在研究中没有观察到与阿瑞吡坦治疗相关的副反应。

  阿瑞吡坦能减轻由于生物制剂治疗所致的严重瘙痒,该药是一个已在临床广泛的老药,因此很容易于增加到治疗方案中。作者指出,就其所知,目前还没有其他试验针对阿瑞吡坦治疗瘙痒的作用进行研究,但是我们的研究结果需要2期和3期临床研究进行进一步验证。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1827465, encodeId=3619182e46518, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Aug 28 08:05:00 CST 2013, time=2013-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864388, encodeId=1a6c186438886, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Nov 16 03:05:00 CST 2012, time=2012-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1825946, encodeId=84e81825946ba, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69223, encryptionId=6191692233a, topicName=生物制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu May 30 02:05:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302543, encodeId=26bf1302543b5, content=<a href='/topic/show?id=b541e1219dc' target=_blank style='color:#2F92EE;'>#瘙痒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71219, encryptionId=b541e1219dc, topicName=瘙痒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d17305, createdName=listen318, createdTime=Mon Oct 01 06:05:00 CST 2012, time=2012-10-01, status=1, ipAttribution=)]
    2013-08-28 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1827465, encodeId=3619182e46518, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Aug 28 08:05:00 CST 2013, time=2013-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864388, encodeId=1a6c186438886, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Nov 16 03:05:00 CST 2012, time=2012-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1825946, encodeId=84e81825946ba, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69223, encryptionId=6191692233a, topicName=生物制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu May 30 02:05:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302543, encodeId=26bf1302543b5, content=<a href='/topic/show?id=b541e1219dc' target=_blank style='color:#2F92EE;'>#瘙痒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71219, encryptionId=b541e1219dc, topicName=瘙痒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d17305, createdName=listen318, createdTime=Mon Oct 01 06:05:00 CST 2012, time=2012-10-01, status=1, ipAttribution=)]
    2012-11-16 minlingfeng
  3. [GetPortalCommentsPageByObjectIdResponse(id=1827465, encodeId=3619182e46518, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Aug 28 08:05:00 CST 2013, time=2013-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864388, encodeId=1a6c186438886, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Nov 16 03:05:00 CST 2012, time=2012-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1825946, encodeId=84e81825946ba, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69223, encryptionId=6191692233a, topicName=生物制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu May 30 02:05:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302543, encodeId=26bf1302543b5, content=<a href='/topic/show?id=b541e1219dc' target=_blank style='color:#2F92EE;'>#瘙痒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71219, encryptionId=b541e1219dc, topicName=瘙痒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d17305, createdName=listen318, createdTime=Mon Oct 01 06:05:00 CST 2012, time=2012-10-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1827465, encodeId=3619182e46518, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Aug 28 08:05:00 CST 2013, time=2013-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864388, encodeId=1a6c186438886, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Nov 16 03:05:00 CST 2012, time=2012-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1825946, encodeId=84e81825946ba, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69223, encryptionId=6191692233a, topicName=生物制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu May 30 02:05:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302543, encodeId=26bf1302543b5, content=<a href='/topic/show?id=b541e1219dc' target=_blank style='color:#2F92EE;'>#瘙痒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71219, encryptionId=b541e1219dc, topicName=瘙痒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d17305, createdName=listen318, createdTime=Mon Oct 01 06:05:00 CST 2012, time=2012-10-01, status=1, ipAttribution=)]
    2012-10-01 listen318
Baidu
map
Baidu
map
Baidu
map